Refractory Multiple Myeloma Clinical Trials in Columbus, Ohio

3 studies are recruiting for refractory multiple myeloma in Columbus, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

    This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Iberdomide is a medication that belongs to a g…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Locations
    15 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT06465316 on ClinicalTrials.gov

  2. Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

    This phase II trial tests how well giving infliximab works for the prevention of cytokine release syndrome (CRS) during treatment with teclistamab or talquetamab in patients with multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refr…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Run by
    Naresh Bumma

    See if you can join NCT07657312 on ClinicalTrials.gov

  3. A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma

    This clinical trial evaluates whether an online cognitive training intervention (Intervention to enhance Cognitive Augmentation and Neuroplasticity [I-CAN]), delivered before and after treatment with chimeric antigen receptor T-cell therapy, works to improve cognitive and neurological outcomes in p…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio
    Run by
    Ohio State University Comprehensive Cancer Center

    See if you can join NCT07609030 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.